Celecoxib and 2,5-dimethyl-celecoxib prevent cardiac remodeling inhibiting akt-mediated signal transduction in an inherited dilated cardiomyopathy mouse model

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 1, 2011, Pages 2-11

  Fan, Xueli ^a   Takahashi Yanaga, Fumi ^a   Morimoto, Sachio ^a   Zhan, Dong Yun ^a   Igawa, Kazunobu ^b   Tomooka, Katsuhiko ^b   Sasaguri, Toshiyuki ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 DIMETHYL CELECOXIB; BETA CATENIN; BRAIN NATRIURETIC PEPTIDE; CELECOXIB; GLYCOGEN SYNTHASE KINASE 3BETA; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; MYOSIN HEAVY CHAIN BETA; PROTEIN KINASE B; TRANSCRIPTION FACTOR 7 LIKE 2; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL; SYSTOLE;

ANIMALS; CARDIOMYOPATHY, DILATED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE KNOCK-IN TECHNIQUES; MICE; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; SIGNAL TRANSDUCTION; SULFONAMIDES; VENTRICULAR REMODELING;

EID: 79959516904     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.179325     Document Type: Article

References (39)

1. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA, and American Heart Association (2007) Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 115:1634-1642. (Pubitemid 46648649)
2. Antos CL, McKinsey TA, Frey N, Kutschke W, McAnally J, Shelton JM, Richardson JA, Hill JA, and Olson EN (2002) Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 99:907-912. (Pubitemid 34106609)
3. Arola A, Tuominen J, Ruuskanen O, and Jokinen E (1998) Idiopathic dilated cardiomyopathy in children: prognostic indicators and outcome. Pediatrics 101:369-376. (Pubitemid 28136408)
4. Basu GD, Pathangey LB, Tinder TL, Gendler SJ, and Mukherjee P (2005) Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res 7:R422-R435.
5. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092-1102. (Pubitemid 40365350)
6. Dannenberg AJ and Subbaramaiah K (2003) Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4:431-436. (Pubitemid 38050040)
7. Dec GW and Fuster V (1994) Idiopathic dilated cardiomyopathy. N Engl J Med 331:1564-1575. (Pubitemid 24366905)
8. Dorn GW 2nd and Force T (2005) Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115:527-537.
9. Du CK, Morimoto S, Nishii K, Minakami R, Ohta M, Tadano N, Lu QW, Wang YY, Zhan DY, Mochizuki M, et al. (2007) Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation. Circ Res 101:185-194. (Pubitemid 47196586)
10. Hanson EL, Jakobs PM, Keegan H, Coates K, Bousman S, Dienel NH, Litt M, and Hershberger RE (2002) Cardiac troponin T lysine 210 deletion in a family with dilated cardiomyopathy. J Card Fail 8:28-32. (Pubitemid 34163847)
11. Haq S, Choukroun G, Kang ZB, Ranu H, Matsui T, Rosenzweig A, Molkentin JD, Alessandrini A, Woodgett J, Hajjar R, et al. (2000) Glycogen synthase kinase-3β is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol 151:117-130.
12. Hardt SE and Sadoshima J (2002) Glycogen synthase kinase-3β: a novel regulator of cardiac hypertrophy and development. Circ Res 90:1055-1063.
13. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, and Chen CS (2000) The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275:11397-11403. (Pubitemid 30212792)
14. Jacobshagen C, Grüber M, Teucher N, Schmidt AG, Unsöld BW, Toischer K, Nguyen VP, Maier LS, Kögler H, and Hasenfuss G (2008) Celecoxib modulates hypertrophic signalling and prevents load-induced cardiac dysfunction. Eur J Heart Fail 10:334-342.
15. Kamisago M, Sharma SD, DePalma SR, Solomon S, Sharma P, McDonough B, Smoot L, Mullen MP, Woolf PK, Wigle ED, et al. (2000) Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 343:1688-1696.
16. Kardosh A, Wang W, Uddin J, Petasis NA, Hofman FM, Chen TC, and Schönthal AH (2005) Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase- 2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo. Cancer Biol Ther 4:571-582. (Pubitemid 41351232)
17. Kenessey A and Ojamaa K (2006) Thyroid hormone stimulates protein synthesis in the cardiomyocyte by activating the Akt-mTOR and p70S6K pathways. J Biol Chem 281:20666-20672. (Pubitemid 44115408)
18. Kerkelä R, Woulfe K, and Force T (2007) Glycogen synthase kinase-3β-actively inhibiting hypertrophy. Trends Cardiovasc Med 17:91-96. (Pubitemid 46518166)
19. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, Fowble JW, Ward PJ, and Chen CS (2004) 3-Phosphoinositide-dependent protein kinase-1/Akt signaling represents a major Cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 64:1444-1451. (Pubitemid 38235615)
20. Lompre AM, Schwartz K, d'Albis A, Lacombe G, Van Thiem N, and Swynghedauw B (1979) Myosin isoenzyme redistribution in chronic heart overload. Nature 282:105-107.
21. Maier TJ, Schilling K, Schmidt R, Geisslinger G, and Grösch S (2004) Cyclooxygenase- 2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 67:1469-1478. (Pubitemid 38388209)
22. Malekar P, Hagenmueller M, Anyanwu A, Buss S, Streit MR, Weiss CS, Wolf D, Riffel J, Bauer A, Katus HA, et al. (2010) Wnt signaling is critical for maladaptive cardiac hypertrophy and accelerates myocardial remodeling. Hypertension 55:939-945.
23. Michels VV, Driscoll DJ, Miller FA, Olson TM, Atkinson EJ, Olswold CL, and Schaid DJ (2003) Progression of familial and non-familial dilated cardiomyopathy: long term follow up. Heart 89:757-761. (Pubitemid 36760636)
24. Miyata S, Minobe W, Bristow MR, and Leinwand LA (2000) Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ Res 86:386-390. (Pubitemid 30141756)
25. Morimoto S (2008) Sarcomeric proteins and inherited cardiomyopathies. Cardiovasc Res 77:659-666.
26. Morimoto S, Lu QW, Harada K, Takahashi-Yanaga F, Minakami R, Ohta M, Sasaguri T, and Ohtsuki I (2002) Ca(2+)-desensitizing effect of a deletion mutation ΔK210 in cardiac troponin T that causes familial dilated cardiomyopathy. Proc Natl Acad Sci USA 99:913-918. (Pubitemid 34106610)
27. Morisco C, Zebrowski D, Condorelli G, Tsichlis P, Vatner SF, and Sadoshima J (2000) The Akt-glycogen synthase kinase 3β pathway regulates transcription of atrial natriuretic factor induced by β-adrenergic receptor stimulation in cardiac myocytes. J Biol Chem 275:14466-14475. (Pubitemid 30339733)
28. Rundell VL, Geenen DL, Buttrick PM, and de Tombe PP (2004) Depressed cardiac tension cost in experimental diabetes is due to altered myosin heavy chain isoform expression. Am J Physiol Heart Circ Physiol 287:H408-H413. (Pubitemid 38802378)
29. Sakoguchi-Okada N, Takahashi-Yanaga F, Fukada K, Shiraishi F, Taba Y, Miwa Y, Morimoto S, Iida M, and Sasaguri T (2007) Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochem Pharmacol 73:1318-1329. (Pubitemid 46452589)
30. Sagnella GA (1998) Measurement and significance of circulating natriuretic peptides in cardiovascular disease. Clin Sci (Lond) 95:519-529.
31. Schönthal AH (2006) Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy. Neurosurg Focus 20:E21.
32. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, Colucci WS, and Walsh K (2005) Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115:2108-2118. (Pubitemid 41134152)
33. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M, et al. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071-1080. (Pubitemid 40365348)
34. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, et al. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-1952. (Pubitemid 30419089)
35. Takahashi-Yanaga F, Yoshihara T, Jingushi K, Miwa Y, Morimoto S, Hirata M, and Sasaguri T (2008) Celecoxib-induced degradation of T-cell factors-1 and -4 in human colon cancer cells. Biochem Biophys Res Commun 377:1185-1190.
36. van de Schans VA, van den Borne SW, Strzelecka AE, Janssen BJ, van der Velden JL, Langen RC, Wynshaw-Boris A, Smits JF, and Blankesteijn WM (2007) Interruption of Wnt signaling attenuates the onset of pressure overload-induced cardiac hypertrophy. Hypertension 49:473-480.
37. Wang YY, Morimoto S, Du CK, Lu QW, Zhan DY, Tsutsumi T, Ide T, Miwa Y, Takahashi-Yanaga F, and Sasaguri T (2010) Up-regulation of type 2 iodothyronine deiodinase in dilated cardiomyopathy. Cardiovasc Res 87:636-646.
38. Wilkins BJ, De Windt LJ, Bueno OF, Braz JC, Glascock BJ, Kimball TF, and Molkentin JD (2002) Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth. Mol Cell Biol 22:7603-7613.
39. Yang HM, Kim HS, Park KW, You HJ, Jeon SI, Youn SW, Kim SH, Oh BH, Lee MM, Park YB, et al. (2004) Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation 110:301-308.